1. Home
  2. STRO vs SCLX Comparison

STRO vs SCLX Comparison

Compare STRO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$16.60

Market Cap

85.0M

Sector

Health Care

ML Signal

HOLD

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$9.27

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRO
SCLX
Founded
2003
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.0M
90.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STRO
SCLX
Price
$16.60
$9.27
Analyst Decision
Hold
Hold
Analyst Count
8
1
Target Price
$18.88
N/A
AVG Volume (30 Days)
131.7K
80.0K
Earning Date
03-12-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$105,646,000.00
$40,360,000.00
Revenue This Year
$63.08
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.23
$3.60
52 Week High
$21.25
$34.27

Technical Indicators

Market Signals
Indicator
STRO
SCLX
Relative Strength Index (RSI) 74.44 27.89
Support Level $14.08 $10.35
Resistance Level $17.33 $12.30
Average True Range (ATR) 1.47 1.05
MACD 0.17 -0.11
Stochastic Oscillator 89.28 6.16

Price Performance

Historical Comparison
STRO
SCLX

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: